Aandeel 603229 ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Zhejiang Ausun Pharmaceutical Co., Ltd.

Aandelen

603229

CNE100002XK2

slotkoers Shanghai S.E.
Andere beurzen
 00:00:00 18-04-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
9,73 CNY -2,41% Intraday-grafiek van Zhejiang Ausun Pharmaceutical Co., Ltd. -4,70% -26,34%
2023 Zhejiang Ausun Pharmaceutical Co, Ltd. Rapporteert winstresultaten voor de negen maanden eindigend op 30 september 2023 CI
2023 Zhejiang Ausun Pharmaceutical Co, Ltd. Rapporteert winstresultaten voor het halfjaar dat eindigde op 30 juni 2023 CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Zhejiang Qizheng Pharmaceutical Co., Ltd. announced that it has received CNY 20 million in funding from Zhejiang Ausun Pharmaceutical Co., Ltd.
Ausun Pharma's Unit Passes Regulatory Inspection
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Zhejiang Qizheng Pharmaceutical Co., Ltd. announced that it expects to receive CNY 20 million in funding from Zhejiang Ausun Pharmaceutical Co., Ltd.
Zhejiang Ausun Pharma Sees Up to 70% Jump in 2022 Profit; Shares Rose 4%
Zhejiang Ausun Pharma Gets Regulatory Nod to Market Azvudine
Zhejiang Ausun Pharmaceutical Co., Ltd. announced that it has received CNY 484.90308 million in funding from Gongqingcheng Shengheng Investment Management Co., Ltd., Shanghai Panjing Investment Management Center (Limited Partnership), Taizhou Financial Holding Asset Management Co., Ltd., and other investors
Marvel Biosciences Completes Manufacturing Milestone Ahead of Phase 1 Trials Targeting Alzheimer's Disease, Depression
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
Zhejiang Ausun Pharmaceutical Co., Ltd.(XSSC:603229) added to S&P Global BMI Index
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
Zhejiang Ausun Pharmaceutical Co., Ltd. announced that it expects to receive CNY 500 million in funding
Zhejiang Ausun Pharmaceutical Co., Ltd. announced that it expects to receive CNY 500 million in funding from Gongqingcheng Shengheng Investment Management Co., Ltd., Shanghai Panjing Investment Management Center (Limited Partnership), Taizhou Financial Holding Asset Management Co., Ltd.
Algernon Pharmaceuticals Inc. Announces Award Contract to Zhejiang Ausun Pharmaceutical Co, Ltd of China to Begin the Manufacturing of Cgmp Supply of Its Repurposed Drug Candidate Np-251
Chinese Shares End Lower; Pharmaceutical Stlocks Suffer Huge Losses After WuXi Biologics' US Sanction
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers 603229
  4. Nieuws Zhejiang Ausun Pharmaceutical Co., Ltd.
  5. Andere talen